ChemioCare CEO Pedro Lichtinger caught up with Proactive's Andrew Scott while in London.
Lichtinger outlines the company's vision which is to transform the current treatment of chemotherapy-induced nausea and vomiting through patch technology.
He says the first patch in their pipeline has completed its development in the lab, it's gone through several tests which prove the blood levels it will deliver in the patient are what they're looking for and they're now working on animals to confirm those blood levels and to check there are no skin irritations or other side effects.
''From there in about 3-4 months we'll go into a proof of concept study in humans ... then in another 3-4 months we'll be in a phase III clinical trial''.
''This will be a small acute trial, you vomit for 5 days, we don't need to follow the patient for a year ...''